Vanguard Group’s Bone Biologics BBLG Stock Holding History

Vanguard Group’s Portfolio BBLG Stock Details BBLG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-23	Closed	-$35K	–	4529
2022 Q3	$35K	Hold	23	–	–	﹤0.01%	4571
2022 Q2	$47K	Hold	23	–	–	﹤0.01%	4590
2022 Q1	$93K	Buy	+23	New	+$83.3K	﹤0.01%	4601

Other funds holding BBLG

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

WAM

Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

CAN

Cetera Advisor Networks El Segundo, California $20.2B AUM 22.31% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Vanguard Group's BBLG Position: Q4 2022 in Review

Vanguard Group sold out of Bone Biologics (BBLG) in Q4 2022, closing a stake of 23 shares — an estimated $35K sold.

Vanguard Group first reported a position in BBLG in Q1 2022 and held it in 3 quarters. The position peaked at $93K in Q1 2022. 10 funds tracked by Wall St. Rank hold BBLG as of Q4 2022.

Vanguard Group reported no remaining Bone Biologics position as of Q4 2022 after selling out during the quarter.
Vanguard Group sold 23 Bone Biologics shares in Q4 2022, an estimated $35K.
Vanguard Group first reported a position in Bone Biologics in Q1 2022 and held it in 3 quarters.
Vanguard Group's Bone Biologics position peaked at $93K in Q1 2022.
10 funds tracked by Wall St. Rank held Bone Biologics as of Q4 2022.

Based on Vanguard Group's 13F filing for Q4 2022, filed 10 Feb 2023.